A Phase 4 interventional study of Capecitabine and Bevacizumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 57 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-27.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.
Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 85th largest by enrollment of the 227 interventional ones that give a count, is one of 13 that started in 2005, is one of 6 in phase 4, and was the 28th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Biostar Pharma, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 146 · Phase 3 55 · Phase 4 6
First in 1998; this study’s year is marked. 13 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 227 interventional studies. Of the 149 that completed or were terminated, 54 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 233 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 100th largest by enrollment of the 170 interventional ones that give a count, is one of 4 that started in 2005, is one of 11 in phase 4, and was the 15th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing capecitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT06764940Biostar Pharma, Inc.A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | 2027-01-15 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
| NCT06247995Novartis PharmaceuticalsA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 233 studies testing capecitabine in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer. Patients received Xeloda 1000 mg/m² orally (PO) twice daily (BID) on Days 1-15, and Avastin 15 mg intravenously (IV) on Day 1 of each 3-week cycle. The anticipated time on study treatment was until disease progression or unacceptable toxicity. The target sample size was \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Capecitabine · Drug: Bevacizumab
1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
Also known as: Xeloda
15 mg IV on Day 1 of each 3-week cycle
Also known as: Avastin
Overall Survival
Overall survival was defined as the time from date of first treatment dose (Day 1) to date of death, across the study phases regardless of the cause of death
Time frame: approximately 505 days (Median Time to Death)
Number of Subjects With Adverse Events
The secondary outcome measure was to evaluate the safety profile, including a summary of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Intensity of AEs were graded according to NCI CTCAE version 3.0 on a 5-point scale: Grade 1=Mild Discomfort, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life Threatening/Disabling and Grade 5=Death. An SAE was defined as any experience that suggested a significant hazard,contraindication, side effect, or precaution.
Time frame: Throughout study
Premature Withdrawal From Study Due to Adverse Events
The secondary outcome measure was to evaluate the safety profile, including a summary of premature withdrawals due to adverse events occurring in more than 1 patient in either study group, by system organ class.
Time frame: Throughout study
Number of Participants With Marked Laboratory Abnormalities
The secondary outcome measure was to evaluate the safety profile, including a summary of marked laboratory abnormalities in \>= 5% of patients. n=number of participants with the laboratory measure,Number=number of participants with the abnormality. Laboratory values were flagged as Low(L) or High(H) if they were below the lower limit or above the upper limit of Roche standard reference range, respectively. Marked laboratory abnormalities (flagged as HH and LL) were defined as those values that were outside the Roche marked reference range and showed a clinically relevant change from baseline.
Time frame: until progressive disease or for up to 3 years
| Milestone | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Started | 109 |
| Completed | 54 |
| Not completed | 55 |
Overall survival was defined as the time from date of first treatment dose (Day 1) to date of death, across the study phases regardless of the cause of death
| Days | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Overall Survival | 505 (420 to 672) |
The secondary outcome measure was to evaluate the safety profile, including a summary of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Intensity of AEs were graded according to NCI CTCAE version 3.0 on a 5-point scale: Grade 1=Mild Discomfort, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life Threatening/Disabling and Grade 5=Death. An SAE was defined as any experience that suggested a significant hazard,contraindication, side effect, or precaution.
| Participants | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev | First Study Treatment Phase Only |
|---|---|---|
| At least 1 adverse event (AE) | 108 | 54 |
| At least 1 treatment-related AE | 104 | 51 |
| At least 1 Grade 3 or 4 AE | 82 | 41 |
| At least 1 serious adverse event (SAE) | 39 | 22 |
| At least 1 AE causing withdrawal | 37 | 25 |
The secondary outcome measure was to evaluate the safety profile, including a summary of premature withdrawals due to adverse events occurring in more than 1 patient in either study group, by system organ class.
| Participants | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev | First Study Treatment Phase Only |
|---|---|---|
| All system organ classes | 25 | 37 |
| General disorders, administration site conditions | 4 | 7 |
| Musculoskeletal and connective tissue disorders | 2 | 6 |
| Respiratory, thoracic and mediastinal disorders | 2 | 5 |
| Renal and urinary disorders | 2 | 2 |
The secondary outcome measure was to evaluate the safety profile, including a summary of marked laboratory abnormalities in \>= 5% of patients. n=number of participants with the laboratory measure,Number=number of participants with the abnormality. Laboratory values were flagged as Low(L) or High(H) if they were below the lower limit or above the upper limit of Roche standard reference range, respectively. Marked laboratory abnormalities (flagged as HH and LL) were defined as those values that were outside the Roche marked reference range and showed a clinically relevant change from baseline.
| Participants | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Hematocrit (fraction) (n=104); Abnormality: Low | 16 |
| Hemoglobin (g/L) (n=104); Abnormality: Low | 18 |
| Platelets (10^9/L) (n=104); Abnormality: Low | 9 |
| Red blood cells (10¹²/L) (n=104); Abnormality: Low | 15 |
| White blood cells (10^9/L)(n=104); Abnormality:Low | 23 |
| Neutrophils (10^9/L) (n=92); Abnormality: High | 14 |
| Neutrophils (10^9/L) (n=92); Abnormality: Low | 25 |
| Prothrombin time (ratio) (n=36); Abnormality: High | 3 |
| Aspartate transaminase(U/L)(n=104)Abnormality:High | 19 |
| Alanine transaminase(U/L)(n=104);Abnormality: High | 10 |
| Alkaline phosphatase(U/L)(n=104);Abnormality: High | 11 |
| Direct bilirubin (umol/L) (n=78);Abnormality: High | 4 |
| Albumin (g/L) (n=104); Abnormality: Low | 13 |
| Total protein (g/L) (n=104); Abnormality: Low | 8 |
| Chloride (mmol/L) (n=104); Abnormality: Low | 5 |
| Calcium (mmol/L) (n=104); Abnormality: Low | 10 |
| Uric acid (umol/L) (n=94); Abnormality: High | 5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev | — | 39/109 (35.8%) | 103/109 (94.5%) |
| Event | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| PainGeneral disorders | 6/109 |
| DehydrationMetabolism and nutrition disorders | 5/109 |
| Chest PainGeneral disorders | 3/109 |
| NauseaGastrointestinal disorders | 3/109 |
| VomitingGastrointestinal disorders | 3/109 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 3/109 |
| Mucosal InflammationGeneral disorders | 2/109 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 2/109 |
| FatigueGeneral disorders | 1/109 |
| Influenza Like IllnessGeneral disorders | 1/109 |
| Event | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 71/109 |
| FatigueGeneral disorders | 68/109 |
| DiarrhoeaGastrointestinal disorders | 66/109 |
| NauseaGastrointestinal disorders | 66/109 |
| ConstipationGastrointestinal disorders | 41/109 |
| VomitingGastrointestinal disorders | 36/109 |
| AnorexiaMetabolism and nutrition disorders | 35/109 |
| AlopeciaSkin and subcutaneous tissue disorders | 32/109 |
| CoughRespiratory, thoracic and mediastinal disorders | 32/109 |
| HeadacheNervous system disorders | 32/109 |
| Age Continuous(Years) | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Mean | 56.7 ± 12.03 |
| Sex: Female, Male(Participants) | Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev |
|---|---|
| Female | 109 |
| Male | 0 |
The record gives a start of Jun 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Bevacizumab